Anatomic pathology selected abstracts
November 2026—Esophageal perforation (EP) is a rare but life-threatening condition, and most cases are due to iatrogenic causes. The remainder occur spontaneously and are due to malignancies or trauma.
Tuesday, December 1, 2026, 1 PM-2 PM ET
Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.
Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, January 12, 2027, 2 PM-3 PM ET
Hear Dr. Roden discuss how computational pathology will impact the practice & future of precision oncology, using global real world analytical evidence for the novel TROP2 NMR biomarker as an example.
Webinar presenter Anja C. Roden, MD, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Science, Rochester, Minnesota
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Roche Diagnostics. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2026—Esophageal perforation (EP) is a rare but life-threatening condition, and most cases are due to iatrogenic causes. The remainder occur spontaneously and are due to malignancies or trauma.
November 2026—B-cell acute lymphoblastic leukemia (B-ALL) arises from a variety of genetic alterations impacting B-cell progenitors. Classification of B-ALL based on genetic type is associated with characteristic morphological, immunophenotypic, or clinical features with prognostic or therapeutic implications, or both.
November 2026
Q. How has the National Comprehensive Cancer Network guideline approach to cytogenetic testing in multiple myeloma evolved, and why does this matter for patient care? Read answer.
Q. If you find smudge cells in a blood smear when performing a manual differential count and their morphological features allow you to classify those cells, do you categorize them as smudge cells or based on their distinct features? At what percentage of smudge cells is an albumin preparation performed? Read answer.
November 2026—Ask a random group of pathologists if they are familiar with lab automation, regardless of whether they use it, and you’re more than likely to get nods of affirmation all around. But follow that up by asking them if they are aware of the pros and cons and ins and outs of robotic process automation versus agentic artificial intelligence and many of those nodding heads may go still.
November 2026—Denials of clinical laboratory, molecular diagnostic, and genomics claims rose to 11.2 percent in 2025 from eight percent in 2024, a 40 percent jump that XiFin says erased two years of improvement, according to the company’s recently released 2026 Payor Denial Impact Report.